WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve ...

PLYMOUTH, Mass.--(BUSINESS WIRE)--IDRx, Inc., a clinical-stage biopharmaceutical company dedicated to transforming cancer treatment with purpose-built precision therapies, today announced updated ...

Progressing lesions of 25 patients with GISTs refractory to ripretinib were sequenced for KIT resistance mutations. Resistant genotypes were validated and characterized using novel cell line models ...

Cogent Biosciences is a biotechnology company focused on developing solutions for complex medical conditions, with a particular focus on Gastrointestinal Stromal Tumors. Bezuclastinib is a promising ...

HT-KIT significantly reduces tumor burden and induces cell death in preclinical GIST models by targeting KIT mutations. Rapid tumor cell death observed within 24 hours of HT-KIT treatment, with ...

A new case report was published in Oncoscience (Volume 10) on September 20, 2023, entitled, "Multi-disciplinary management of recurrent gastrointestinal stromal tumor harboring KIT exon 11 mutation ...

Patients with GIST have more treatment options than ever, with others currently under development. On a summer Sunday in 2011, Lee Keenan competed in the Pleasant Prairie Triathlon in Wisconsin. At 42 ...

GSK plc (NYSE:GSK) agreed to acquire IDRx, Inc., a biopharmaceutical company focused on precision therapeutics for gastrointestinal stromal tumors (GIST), for $1 billion. Under the agreement, GSK ...

Acquisition includes IDRX-42, a highly selective KIT tyrosine kinase inhibitor (TKI) designed to treat gastrointestinal stromal tumours (GIST) IDRX-42 offers potential to address all key KIT mutations ...